Literature DB >> 3510773

Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure.

E S Monrad, D S Baim, H S Smith, A S Lanoue.   

Abstract

To assess their comparative effects on hemodynamics and myocardial energetics, we administered nitroprusside (1.5 +/- 0.6 microgram/kg-min), dobutamine (10 +/- 3 micrograms/kg-min), and milrinone (67 +/- 13 micrograms/kg-min) sequentially to 10 patients with severe (NYHA class III or IV) congestive heart failure. Each agent led to a significant (p = .001) increase in cardiac index (1.9 +/- 0.5 to 2.7 +/- 0.6 liters/min/m2; 1.7 +/- 0.4 to 2.6 +/- 0.6 liters/min/m2; and 1.8 +/- 0.5 to 2.7 +/- 0.5 liters/min/m2, for nitroprusside, dobutamine, and milrinone, respectively). Dobutamine did not produce a significant change in the pulmonary capillary wedge pressure (27 +/- 5 to 24 +/- 6 mm Hg, NS) nor in mean arterial pressure (83 +/- 9 to 86 +/- 10 mm Hg, NS), but caused a significant rise in heart rate (85 +/- 16 to 99 +/- 17 beats/min, p = .001) and in myocardial oxygen consumption (8.7 +/- 2.1 to 11.1 +/- 3.8 ml O2/min, p = .03). In contrast, nitroprusside and milrinone each caused a significant (p = .001) fall in the pulmonary capillary wedge pressure (27 +/- 6 to 19 +/- 7 mm Hg and 26 +/- 6 to 19 +/- 9 mm Hg, respectively), without significantly increasing either the heart rate (87 +/- 18 to 85 +/- 17 beats/min and 86 +/- 17 to 89 +/- 17 beats/min, respectively) or myocardial oxygen consumption (8.8 +/- 2.3 to 7.6 +/- 2.1 ml O2/min and 8.8 +/- 2.1 to 8.4 +/- 2.1 ml O2/min, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3510773

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  23 in total

1.  Computational analysis of the effect of the type of LVAD flow on coronary perfusion and ventricular afterload.

Authors:  Ki Moo Lim; In Su Kim; Seong Wook Choi; Byung Goo Min; Yong Soon Won; Heon Young Kim; Eun Bo Shim
Journal:  J Physiol Sci       Date:  2009-04-23       Impact factor: 2.781

2.  Impact of milrinone on mitral annular velocity in patients with congestive heart failure.

Authors:  Yasuyuki Hadano; Hiroshi Ogawa; Takatoshi Wakeyama; Akira Takaki; Takahiro Iwami; Masayasu Kimura; Mamoru Mochizuki; Yosuke Miyazaki; Atsushi Hiratsuka; Masunori Matsuzaki
Journal:  J Med Ultrason (2001)       Date:  2012-10-10       Impact factor: 1.314

Review 3.  Management of diuretic-refractory, volume-overloaded patients with acutely decompensated heart failure.

Authors:  Jonathan D Sackner-Bernstein
Journal:  Curr Cardiol Rep       Date:  2005-05       Impact factor: 2.931

Review 4.  Milrinone. A preliminary review of its pharmacological properties and therapeutic use.

Authors:  R A Young; A Ward
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

5.  Population pharmacokinetics of olprinone in patients undergoing cardiac surgery with cardiopulmonary bypass.

Authors:  Tsunehisa Tsubokawa; Syuichi Ishizuka; Kyoko Fukumoto; Kazuyuki Ueno; Ken Yamamoto
Journal:  J Anesth       Date:  2012-10-23       Impact factor: 2.078

6.  The effect of milrinone on the right ventricular function in patients with reduced right ventricular function undergoing off-pump coronary artery bypass graft surgery.

Authors:  Jong Hwa Lee; Young Jun Oh; Yon Hee Shim; Yong Woo Hong; Gijong Yi; Young Lan Kwak
Journal:  J Korean Med Sci       Date:  2006-10       Impact factor: 2.153

7.  Cardioprotection induced by olprinone, a phosphodiesterase III inhibitor, involves phosphatidylinositol-3-OH kinase-Akt and a mitochondrial permeability transition pore during early reperfusion.

Authors:  Shinya Tosaka; Tetsuji Makita; Reiko Tosaka; Takuji Maekawa; Sungsam Cho; Tetsuya Hara; Hiroyuki Ureshino; Koji Sumikawa
Journal:  J Anesth       Date:  2007-05-30       Impact factor: 2.078

Review 8.  Intravenous vasodilator therapy in congestive heart failure.

Authors:  Kourosh Moazemi; Jatinder S Chana; Anna Marie Willard; Abraham G Kocheril
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 9.  Phosphodiesterase inhibitors. Do the risks outweight the benefits?

Authors:  R Andrews; A J Cowley
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

Review 10.  New medical therapies for heart failure.

Authors:  Thomas G von Lueder; Henry Krum
Journal:  Nat Rev Cardiol       Date:  2015-09-29       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.